[{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cholecalciferol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Srage 3 Diabetes Mellitus, Type 1.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 13, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 21, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 09, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Diamyd

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 15, 2024

                          Lead Product(s) : GAD-alum,Vitamin D3

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease.

                          Product Name : ImmunD3 Nutri-Strips

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Vitamin D3

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank